-------------------------------------------------------

Visit amazon.com for purchasing the book..

Online Donations

Please Donate If You feel this site is good and knowledge
resource of books or literature:

https://www.akshayapatra.org/onlinedonations

You can help the site by posting and/or telling your friends+colleagues about this place :)
Before God we are all equally wise - and equally foolish-Albert Einstein
Get your own Wavy Scroller
(Knowledge is not power; the ability to use that knowledge is power )

© Copyright 2009 Scientist. All rights reserved.

Disclaimer: Scientist-At-Work does not store any files on its server. We only index and link to webpages on, and provided by, other third-party websites.

"Use your head - I did!"
Showing posts with label Stability Studies. Show all posts
Showing posts with label Stability Studies. Show all posts

Thursday, April 8, 2010

Useful Pharmaceutical Links

Analytical Method Development
Analytical Method Validation
Validated analytical method only can give accurate results. Validation of analytical method is must for pharmaceutical analytical laboratory.
There is guideline for analytical method validation from ICH & US FDA.
ICH-Q2(R1)- Validation of Analytical Procedures - Text and Methodology
US FDA draft guidance on analytical procedures & method validation
EDQM guideline

EDQM-Validation of analytical procedure

Analytical Method Transfer

There is no definite guidance from USFDA on this subject. Recently USP has come up with a stimuli article on this subject. For more information refer the link below.
Transfer of analytical procedures-A new general information chapter

Instrument calibration
1. Disolution Apparatus 1 & 2 - Mechanical calibration
2. Prednisone tablet for PVT - New lot - P1I303

Instrument Qualification

Annex 1: Qualification of HPLC Equipment

Annex 2: Qualification of GC Equipment

Annex 3: Qualification of UV-Visible Spectrophotometers

Annex 4: Qualification of IR Spectrophotometers


Result & Reports
Out-Of-Specification (OOS)
Investigation is must for any product failures to find out the root cause and Corrective And Preventive Action(CAPA). USFDA come up with definite guidance on this subject. This guideline helps to handle OOS data and procedure for investigation. For more information refer the below link.

Out-Of-Trend(OOT) Analytical Results
An analytical result which fall in with in the specification limit but does not follow with in the trend or unexpected result. Normally any analytical result which fall in Out-Of-Specification requires a detailed investigation to find a root cause failure and folowed by a currettive And Preventive Action(CAPA).
Though regulation demands investigation to be completed with in thirty days but most of the cases industries fails to complete the invsetigation with in stipulated period to find root cause.Meanwhile its end up with few more failures. To avoid such things happen the current practice starts investigation when results appear to be ou-of-trend.
The following links help to know more about OOT
Auditing pharmaceuticals quality control Laboratory

Auditing quality control laboratory is must for continuous improvement and regualotory requirements. It helps to keep QC laboratory in high compliance level and maintain best practices through continuos improvement by training and gap analysis.

There is a guideline from US FDA for inspection pharmaceuticals QC laboratory it

includes chemical lab and Micro lab.

Auditing Guide from APIC

Pharmaceutical Quality Control Labs

Audit check list for Pharmaceutical Quality Control Labs by PICScheme

Microbiological Pharmaceutical Quality Control Labs
Guidance document on part 11-Electronic signature & Electronic record

NEW: Annex 1: Validation of computerised calculation systems: example of validation of in-house software - Spread sheet/Microsoft Excel

NEW: Annex 2: Validation of Databases (DB), Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebooks (ELN)

NEW: Annex 3: Validation of computers as part of test equipment

GAMP 4 to GAMP 5 -Summary


Elemental Impurities—Comments and Responses (1.1MB)

Flow Microscopy—Dynamic Image Analysis for Particle Counting (1.1MB)

A Recombinant Factor C Procedure for the Detection of Gram-negative Bacterial Endotoxin (1.7MB)

High level list of Australian and International pharmaceutical regulations and standards

REGULATIONS

Australian


Australian Code of Good Manufacturing Practice for Medicinal Products – Therapeutics Goods Administration 16 August 2002.

Australian Code of Good Manufacturing Practice for Veterinary Chemical Products – Australian Pesticides & Veterinary Medicines Authority.

Australian Regulatory Guidelines for Complementary Medicines – Therapeutics Goods Administration June 2005.

Australian Medical Device Guidelines – Therapeutics Goods Administration

International

United States
Code of Federal Regulations 21CFR 210 - cGMP in Manufacturing, Processing, Packing, or holding of Drugs; General – U.S. Food & Drug Administration

Code of Federal Regulations 21CFR 211 cGMP for Finished Pharmaceuticals – U.S. Food & Drug Administration

Code of Federal Regulations 21CFR 600 - Biologics – U.S. Food & Drug Administration

Europe
Eudralex Volume 4 - Medicinal Products for Human and Veterinary Use : Good Manufacturing Practice – European Commission

Links to the Associations and Affiliations including general pharma, engineering, scientific and project management.

General Pharmaceutical

  • Pharmaceutical Inspection Cooperation Scheme (PIC/S)
    www.picscheme.org
  • World Health Organisation (WHO)
    www.who.int

  • Parental Drug Association (PDA) Home Page – Intramuscular and Intravenous drug news and information.
    www.pda.org


  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) – scientific and technical aspects of product registration.
    www.ich.org


Engineering

  • International Society of Pharmaceutical Engineering (ISPE) Home Page – worlds largest non-profit professional organisation serving pharmaceutical and biotech manufacturing professionals.
    www.ispe.org
  • Engineers Australia Home Page – Revised and updated Institution of Engineers Australia (IEAust) Home Page. General information and news for all aspects of engineering in Australia.
    www.engineersaustralia.org.au


  • Association of Professional Engineers, Scientists and Managers, Australia (APESMA) Home Page
    www.apesma.asn.au

Scientific

  • Biospectrum Asia Home Page – Informative website on the pharma/biotech industries in Asia.
    www.biospectrumasia.com

  • Australia’s Biotechnology Organisation (Ausbiotech) Home Page – Australia wide biotechnology information website.
    www.ausbiotech.org
  • BioGeelong Home Page – News, links and information on the growing Geelong Biotechnology industry.
    www.biogeelong.com.au

Project Management

  • Project Management Institute (PMI) Home Page – Project Management resource website including standards, seminars, education programs and case studies.
    www.pmi.org

Others



Thursday, April 30, 2009

Impurities Evaluation of Pharmaceuticals


Impurities Evaluation of Pharmaceuticals.
Publisher: Informa HealthCare | ISBN: 0824798848 | edition 1998 | PDF | 304 pages | 11,74 mb

Filling a gap in the pharmaceutical literature, this unique guide addresses the development of targeted methodologies to monitor impurities in pharmaceutical compounds and drug products. Furnishes physicochemical protocols to determine the purity of pharmaceutical compounds fully before pharmacological and toxicological studies begin! Providing a clear definition of the subject, Impurities Evaluation of Pharmaceuticals introduces various techniques for isolating and characterizing impurities presents guidelines to evaluate stability using kinetic studies shows how to develop stability-indicating methodologies details various methods that require minimal sample prepreparation gives regulatory perspectives on chiral impurities and more! Containing important literature citations and offering an invaluable list of applications, Impurities Evaluation of Pharmaceuticals is an outstanding resource for pharmacists and pharmacologists clinical microbiologists, quality assurance and production managers in the pharmaceutical industry, analytical chemists and biochemists, pharmaceutical regulatory personnel, and upper-level undergraduate, graduate, and continuing-education students in these disciplines.

DOWNLOAD LINK:
http://depositfiles.com/en/files/jov7g2ml4

Wednesday, April 22, 2009

Colloidal Silica: Fundamentals and Applications


Colloidal Silica: Fundamentals and Applications.
CRC Press | ISBN: 0824709675 | 2005-12-19 | PDF | 912 pages | 17.33 Mb | RS

In spite of the apparent simplicity of silica's composition and structure, scientists are still investigating fundamental questions regarding the formation, constitution, and behavior of colloidal silica systems. Colloidal Silica: Fundamentals and Applications introduces new information on colloid science related to silica chemistry as well as theoretical and experimental aspects of significant areas of colloidal silica science and technology. This resource is dedicated to helping researchers find new uses of silica and answers to practical problems as its industrial use continues to grow steadily in traditional and novel areas. Written by leading silica scientists around the world, this book reflects developments in the field since silica scientist Ralph K. Iler published his authoritative book on silica chemistry in 1979. It discusses properties and methods of characterization, synthesis, and preparation of silica in terms of industrial applications. Following an analysis of the surface chemistry of various silicas, the book explores methods for measuring particle size and useful characterization techniques for determining structure, stability, and reactivity. The authors then focus on various studies, analytical methods, and current applications involving silica gels and powders, silica coatings, colloidal silica, and sol-gel technology. Colloidal Silica: Fundamentals and Applications features up-to-date material relating to fields as diverse as catalysis, metallurgy, electronics, glass, ceramics, paper and pulp technology, optics, elastomers, food, health care, and industrial chromatography. It is ideal for scientists interested in silica chemistry and physics as well as those not familiar with the subject.

DOWNLOAD LINK:

Thursday, March 26, 2009

DRUGS:PHOTOCHEMISTRY

DRUGS:PHOTOCHEMISTRY.
By A. ALBINI, E. FASINI
  • Publisher: Royal Society of Chemistry
  • Number Of Pages: 354
  • Publication Date: 1998-10-09
  • ISBN-10 / ASIN: 0854047433
  • ISBN-13 / EAN: 9780854047437
Product Description:

Presents the basic elements of the science, & serves as an excellent introduction to this emerging field of photochemistry. Detailed experimental conditions for photostability studies are given, along with a discussion of the recently implemented ICH Guidelines for drug photostability.

DOWNLOAD LINK:

Sunday, March 1, 2009

Stability of Drugs and Dosage Forms

By Sumie Yoshioka, Valentino J. Stella,
  • Publisher: Springer
  • Number Of Pages: 272
  • Publication Date: 2000-11
  • Sales Rank: 351264
  • ISBN / ASIN: 0306464047
  • EAN: 9780306464041
  • Binding: Hardcover
  • Manufacturer: Springer
  • Studio: Springer
  • Average Rating:
  • Total Reviews:

Book Description:

Drug products are complex mixtures of drugs and excipients and, as such, their chemical and physical stability kinetics are complex. This book discusses the stability of these dosage forms with preformulation studies through to the studies on the final products. The book is intended for graduate students, researchers and professionals in the field of Pharmaceutics and Pharmaceutical Chemistry.

DOWNLOAD LINK:

http://rapidshare.com/files/50663431/stability_of_drugs_and_dosage_forms.pdf

Sunday, January 11, 2009

What are Compendial and non-Compendial analytical procedures ? What is analytical validation

What are Compendial and non-Compendial analytical procedures ? What is analytical validation ?

Compendial is nothing but Pharmacopoeial and non-com pendial is nothing but non-Pharmacopoeial. The analytical procedure refers to the way of performing the analysis. It should describe in detail the steps necessary to perform each analytical test. This may include, but is not limited to, the sam ple, the reference standard and the reagents preparations, use of the apparatus, generation of the calibration curve, use of the formulae for the calculation, etc.
Standard parameters for inclusion in a study of analytical validation:
Specificity / Selectivity
Accuracy
Precision
Linearity and Range
LOD / LOQ
Ruggedness
Standard and Sample Solution Stability
Robustness (Optional)

Specificity / Selectivity : Specificity is the ability to assess unequivocally the analyte in the presence of com ponents which may be expected to be present. Typically these might include impurities, degradants, matrix, etc.

Lack of specificity of an individual analytical procedure may be com pensated by other supporting analytical procedure(s).

This definition has the following implications:

Identification: to ensure the identity of an analyte.

Purity Tests: to ensure that all the analytical procedures performed allow an accurate statement of the
content of impurities of an analyte, i.e. related substances test, heavy metals, residual solvents content, etc.

Assay (content or potency): to provide an exact result which allows an accurate statement on the content or potency of the analyte in a sam ple.

Accuracy : The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found. This is sometimes termed trueness.

Precision :

The precision of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sam pling of the sam e homogeneous sam ple under the prescribed conditions. Precision may be considered at three levels: repeatability, intermediate precision and reproducibility.

Precision should be investigated using homogeneous, authentic sam ples. However, if it is not possible to obtain a homogeneous sam ple it may be investigated using artificially prepared sam ples or a sam ple solution.

The precision of an analytical procedure is usually expressed as the variance, standard deviation or coefficient of variation of a series of measurements.

Repeatability :Repeatability expresses the precision under the sam e operating conditions over a short interval of time. Repeatability is also termed intra-assay precision.

Intermediate Precision : Intermediate precision expresses within-laboratories variations: different days, different analysts, different equipment, etc.

Reproducibility : Reproducibility expresses the precision between laboratories (collaborative studies, usually applied to standardization of methodology).

Detection Limit (LOD) : The detection limit of an individual analytical procedure is the lowest amount of analyte in a sam ple which can be detected but not necessarily quantitated as an exact value.

Several approaches for determining the detection limit are possible, depending on whether the procedure is a non- instrumental or instrumental. Approaches other than those listed below may be acceptable.

Based on Visual Evaluation : Visual evaluation may be used for non-instrumental methods but may also be used with instrumental methods. The detection limit is determined by the analysis of sam ples with known concentrations of analyte and by establishing the minimum level at which the analyte can be reliably detected.

Based on Signal-to-Noise : This approach can only be applied to analytical procedures which exhibit baseline noise. Determination of the signal-to-noise ratio is performed by com paring measured signals from sam ples with known low concentrations of analyte with those of blank sam ples and establishing the minimum concentration at which the analyte can be reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally considered acceptable for estimating the detection limit.

Based on the Standard Deviation of the Response and the Slope : The detection limit (DL) may be expressed as : DL = 3.3 Stddev / S

where = the standard deviation of the response
S = the slope of the calibration curve

The slope S may be estimated from the calibration curve of the analyte. The estimate of  may be carried out in a variety of ways, for example:

Based on the Standard Deviation of the Blank : Measurement of the magnitude of analytical background response is performed by analyzing an appropriate number of blank sam ples and calculating the standard deviation of these responses.

Based on the Calibration Curve : A specific calibration curve should be studied using sam ples containing an analyte in the range of DL. The residual standard deviation of a regression line or the standard deviation of y-intercepts of regression lines may be used as the standard deviation.

Quantitation Limit (LOQ) : The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sam ple which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of com pounds in sam ple matrices, and is used particularly for the determination of impurities and/or degradation products.

Several approaches for determining the quantitation limit are possible, depending on whether the procedure is a non- instrumental or instrumental. Approaches other than those listed below may be acceptable.

Based on Visual Evaluation : Visual evaluation may be used for non-instrumental methods but may also be used with instrumental methods. The quantitation limit is generally determined by the analysis of sam ples with known concentrations of analyte and by establishing the minimum level at which the analyte can be quantified with acceptable accuracy and precision.

Based on Signal-to-Noise Approach : This approach can only be applied to analytical procedures that exhibit baseline noise. Determination of the signal-to-noise ratio is performed by com paring measured signals from sam ples with known low concentrations of analyte with those of blank sam ples and by establishing the minimum concentration at which the analyte can be reliably quantified. A typical signal-to-noise ratio is 10:1.

Based on the Standard Deviation of the Response and the Slope : The quantitation limit (QL) may be expressed as: QL = 10 Stddev / S

W here = the standard deviation of the response
S = the slope of the calibration curve

The slope S may be estimated from the calibration curve of the analyte. The estimate of  may be carried out in a variety of ways for example:

Based on Standard Deviation of the Blank : Measurement of the magnitude of analytical background response is performed by analyzing an appropriate number of blank sam ples and calculating the standard deviation of these responses.

Based on the Calibration Curve : A specific calibration curve should be studied using sam ples, containing an analyte in the range of QL. The residual standard deviation of a regression line or the standard deviation of y-intercepts of regression lines may be used as the standard deviation.

Linearity : The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sam ple.

Range : The range of an analytical procedure is the interval between the upper and lower concentration (amounts) of analyte in the sam ple (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity.
Robustness : The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during normal usage.
Examples of typical variations are:
- stability of analytical solutions;
- extraction time.

In the case of liquid chromatography, examples of typical variations are:

- influence of variations of pH in a mobile phase;
- influence of variations in mobile phase com position;
- different columns (different lots and/or suppliers);
- temperature;
- flow rate.
In the case of gas-chromatography, examples of typical variations are:
- different columns (different lots and/or suppliers);
- temperature;
- flow rate.

Sample Solution Stability : This study determines the time period after sam ple preparation during which the com pound of interest remains stable in the HPLC apparatus under the described analytical conditions. Data to support the sam ple solution stability under normal laboratory conditions for the duration of the test procedures, e.g., 24 hours should be generated and provides an indication of its reliability during normal usage.

Other points to consider include:

Capacity Factor (k') : The capacity factor is a measure of where the peak of interest is located with respect to the
void volume, i.e., elution time of the non-retained com ponents. The peak should be well resolved from other peaks
and the void volume. Generally, the value of k' is >2.

Precision/Injection repeatability (RSD) Injection precision expressed as RSD (relative standard deviation) or coefficient of variation (C.V.) indicates the performance of the HPL chromatograph which includes the plumbing, column, and environmental conditions, at the time the sam ples are analysed. It should be noted that sam ple preparation and manufacturing variations are not considered. A C.V. of ≤ 1% for n ≥ 5 is desirable.

Relative retention ( α ) : Relative retention is a measure of the relative location of two peaks. This is not an essential parameter as long as the resolution (R s) is stated.


Resolution (Rs) : Rs is a measure of how well two peaks are separated. For reliable quantitation, well separated peaks are essential for quantitation. This is a very useful parameter if potential interference peak(s) may be of concern. The closest potential eluting peak to the analyte should be selected.

Rs of >2 between the peak of interest and the closest potential interfering peak (impurity, excipient, degradation product, internal standard, etc.) is desirable.

Tailing factor (T) : The tailing factor, a measure of peak sym metry, is unity for perfectly sym metrical peaks and its value increases as tailing becom es more pronounced. As peaks asym metry increases, integration and hence precision becom es less reliable. T of ≤ 2 is desirable.

Theoretical plate number (N) :Theoretical plate number is a measure of column efficiency, i.e., how many peaks can be located per unit run-time of the chromatogram.

N is fairly constant for each peak on a chromatogram with a fixed set of operating conditions. H or HETP, the height equivalent of a theoretical plate, measures the column efficiency per unit length (L) of the column.

Parameters which can affect N or H include peak position, particle size in column, flow rate of mobile phase, column temperature, viscosity of mobile phase and molecular weight of the analyte.

The theoretical plate number depends on elution time but in general should be >2000.

Methods have been developed and validated in the following technologies:

Confirmation of identity by NMR, IR, MS
Assay of com ponents by GC, HPLC, W et Chemistry
Organic impurities by GC, Ion chromatography Trace elements and ions by Ion Chromatography Chiral Purity by NMR and Chromatographies

A wide range of physical property measurements on products and formulations can also be carried, for example, viscosity (for liquid products), porosity (for marcroporous materials), and XRD (for crystalline materials).

Saturday, November 15, 2008

Statistical Design and Analysis of Stability Studies (Chapman & Hall/Crc Biostatistics Series)

Statistical Design and Analysis of Stability Studies (Chapman & Hall/Crc Biostatistics Series)By Shein-Chung Chow
Publisher: Chapman & Hall/CRC
Number Of Pages: 352
Publication Date: 2007-05-30
ISBN-10 / ASIN: 1584889055
ISBN-13 / EAN: 9781584889052
Binding: Hardcover
Product Description:
The US Food and Drug Administration's Report to the Nation in 2004 and 2005 indicated that one of the top reasons for drug recall was that stability data did not support existing expiration dates. Pharmaceutical companies conduct stability studies to characterize the degradation of drug products and to estimate drug shelf life. Illustrating how stability studies play an important role in drug safety and quality assurance, Statistical Design and Analysis of Stability Studies presents the principles and methodologies in the design and analysis of stability studies. After introducing the basic concepts of stability testing, the book focuses on short-term stability studies and reviews several methods for estimating drug expiration dating periods. It then compares some commonly employed study designs and discusses both fixed and random batch statistical analyses. Following a chapter on the statistical methods for stability analysis under a linear mixed effects model, the book examines stability analyses with discrete responses, multiple components, and frozen drug products. In addition, the author provides statistical methods for dissolution testing and explores current issues and recent developments in stability studies. To ensure the safety of consumers, professionals in the field must carry out stability studies to determine the reliability of drug products during their expiration period. This book provides the material necessary for you to perform stability designs and analyses in pharmaceutical research and development.
DOWNLOAD LINK:

Sunday, October 12, 2008

Corrosion of Ceramic and Composite Materials, Second Edition

Product Description
Corrosion of Ceramic and Composite Materials, Second Edition is a primary source of guidance for the assessment, interpretation, and inhibition of corrosion phenomena. This book discusses all aspects of corrosion of ceramics, including environments, mechanisms, and materials, and the means to minimize or eliminate corrosion. The author compiles key findings and literature highlights from nearly a decade of scientific advancement, covering emerging techniques in corrosion analysis, characterization, and prediction. He provides at-a-glance coverage of national and international testing procedures for the evaluation of materials stability. The book covers the fundamentals of corrosion by gases, liquids, and solids of several ceramic materials including crystalline materials, glasses, composites, bioceramics, and advanced ceramics. It also discusses property/corrosion relationships and testing. The book collects a generous number of models, figures, and studies illustrating techniques to minimize and reduce the effects of various mechanisms contributing to the corrosion of civil, aerospace, and military structures. The second edition includes a review of all the current literature since publication of the first edition, an additional chapter on composites, and major sections added on bioceramics and weathering of construction materials. Corrosion of Ceramic and Composite Materials, Second Edition explains existing corrosion problems and offers an excellent guide to the design and development of corrosion-resistant structures.
Product Details
Hardcover: 408 pages
Publisher: CRC; 2 edition
(June 23, 2004)
Language: English
ISBN-10: 0824753666
ISBN-13: 978-0824753665
Product Dimensions: 9 x 6.1 x 0.9 inches
Shipping Weight: 1.5 pounds.
DOWNLOAD LINK:

http://ifile.it/lsf0tj/__7574b16__via_gigapedia.info__.html


Friday, October 10, 2008

Statistical Design and Analysis of Stability Studies

Statistical Design and Analysis of Stability Studies (Chapman & Hall/Crc Biostatistics Series)
By Shein-Chung Chow

  • Publisher: Chapman & Hall/CRC
  • Number Of Pages: 352
  • Publication Date: 2007-05-30
  • ISBN-10 / ASIN: 1584889055
  • ISBN-13 / EAN: 9781584889052
  • Binding: Hardcover

Product Description:

The US Food and Drug Administration's Report to the Nation in 2004 and 2005 indicated that one of the top reasons for drug recall was that stability data did not support existing expiration dates. Pharmaceutical companies conduct stability studies to characterize the degradation of drug products and to estimate drug shelf life. Illustrating how stability studies play an important role in drug safety and quality assurance, Statistical Design and Analysis of Stability Studies presents the principles and methodologies in the design and analysis of stability studies. After introducing the basic concepts of stability testing, the book focuses on short-term stability studies and reviews several methods for estimating drug expiration dating periods. It then compares some commonly employed study designs and discusses both fixed and random batch statistical analyses. Following a chapter on the statistical methods for stability analysis under a linear mixed effects model, the book examines stability analyses with discrete responses, multiple components, and frozen drug products. In addition, the author provides statistical methods for dissolution testing and explores current issues and recent developments in stability studies. To ensure the safety of consumers, professionals in the field must carry out stability studies to determine the reliability of drug products during their expiration period. This book provides the material necessary for you to perform stability designs and analyses in pharmaceutical research and development.

DOWNLOAD LINK:

http://rapidshare.com/files/114249125/1584889055.rar

Sunday, September 21, 2008

Stability of drugs and dosage forms

By Sumie Yoshioka, Valentino J. Stella,
  • Publisher: Springer
  • Number Of Pages: 272
  • Publication Date: 2000-11
  • Sales Rank: 351264
  • ISBN / ASIN: 0306464047
  • EAN: 9780306464041
  • Binding: Hardcover
  • Manufacturer: Springer
  • Studio: Springer
  • Average Rating:
  • Total Reviews:

Book Description:

Drug products are complex mixtures of drugs and excipients and, as such, their chemical and physical stability kinetics are complex. This book discusses the stability of these dosage forms with preformulation studies through to the studies on the final products. The book is intended for graduate students, professionals in the field of Pharmaceutics and Chemistry.

http://rapidshare.com/files/50663431/stability_of_drugs_and_dosage_forms.pdf

http://rapidshare.com/files/50694531/stability_drugs_dosage_forms.zip


Friday, September 12, 2008

Photostability Of Drugs And Drug Formulations, 2nd Edition

Publisher: CRC
  • Number Of Pages: 560
  • Publication Date: 2004-05-12
  • Sales Rank: 539363
  • ISBN / ASIN: 0415303230
  • EAN: 9780415303231
  • Binding: Hardcover
  • Manufacturer: CRC
Book Description:
Providing the guidance needed for formulation, handling, and quality control of photolabile drugs, Photostability of Drugs and Drug Formulations, Second Edition explores the significance of new information on drug photoreactivity in a pharmaceutical context. Completely revised and updated, with chapter authors drawn from an international panel of experts, the book supplies the background necessary for planning standardized photochemical stability studies as a part of drug development and formulation work. It contains comprehensive coverage of the physical and chemical aspects of drug photoreactivity, formulation, stability testing, and drug design/discovery in one resource. The contents have been reorganized to focus on the standardization of photostability testing of drug substances and products, in vitro photoreactivity screening of drugs, and various aspects of the formulation of photoreactive substances. The information on in vitro screening of drug photoreactivity is of great relevance for scientists who are developing and validating a set of testing protocols to address photosafety. Discussing kinetic and chemical aspects of drug photodecomposition as well as the practical problems frequently encountered in photochemical stability testing, this book helps you design a test protocol and interpret the results. Features · Assists non-experts in this field design a test protocol and interpret the results · Covers in vitro and in vivo aspects of interactions between drugs and light · Explores the kinetic and chemical aspects of drug photodecomposition · Discusses the problems frequently encountered in photochemical stability testing · Provides guidance on how to address photosafety assessments and labeling requirements of potentially photoreactive drugs · Highlights the practical implications of drug photodecomposition from a pharmaceutical viewpoint · Offers specific guidance in photostability testing and screening of drug photoreactivity.

http://rapidshare.com/files/77385899/Photostability_Of_Drugs_And_Drug_Formulations.rar


Saturday, September 6, 2008

Handbook of Modern Pharmaceutical Analysis

Publisher: Academic Press
  • Number Of Pages: 600
  • Publication Date: 2001-07-27
  • ISBN-10 / ASIN: 0120455552
  • ISBN-13 / EAN: 9780120455553
  • Binding: Hardcover
Product Description:

This book describes the role modern pharmaceutical analysis plays in the development of new drugs. Detailed information is provided as to how the quality of drug products is assured from the point of discovery until the patient uses the drug. Coverage includes state-of-the-art topics such as analytics for combinatorial chemistry and high-throughput screening, formulation development, stability studies, international regulatory aspects and documentation, and future technologies that are likely to impact the field. Emphasis is placed on current, easy-to-follow methods that readers can apply in their laboratories.

No book has effectively replaced the very popular text, Pharmaceutical Analysis, that was edited in the 1960s by Tak Higuchi. This book will fill that gap with an up-to-date treatment that is both handy and authoritative.

RapidShare

Tuesday, August 19, 2008

Identification and Determination of Impurities in Drugs (Progress in Pharmaceutical and Biomedical Analysis - Volume 4)(GOOD BOOK)

Identification and Determination of Impurities in Drugs (Progress in Pharmaceutical and Biomedical Analysis)

By S. Görög

Publisher: Elsevier Science

Number Of Pages: 772

Publication Date: 2000-05-01

ISBN-10 / ASIN: 0444828990


ISBN-13 / EAN: 9780444828996


Binding: Hardcover

Impurity profiling is the common name of a group of analytical activities, the aim of which is the detection, identification/structure elucidation and quantitative determination of organic and inorganic impurities, as well as residual solvents in bulk drugs and pharmaceutical formulations. Since this is the best way to characterise the quality and stability of bulk drugs and pharmaceutical formulations, this is the core activity in modern drug analysis.

Due to the very rapid development of the analytical methodologies available for this purpose and the similarly rapid increase of the demands as regards the purity of drugs it is an important task to give a summary of the problems and the various possibilities offered by modern analytical chemistry for their solution. That is the aim of this book.

The book is methodology-oriented. In the first chapter some important aspects of the background of impurity-related analytical studies (toxicological, pharmacopoeial aspects, the characterisation of the sources of impurities and the role of impurity profiling in various fields of drug research, production and therapeutic use) are summarised. Chapter two deals with related organic impurities, the strategies for impurity profiling, the use of chromatographic and related separation methods, spectroscopic, and hyphenated techniques. The subject of the third chapter is the identification and determination of residual solvents. The determination of inorganic impurities is discussed in chapter four. The special problems of degradation products as impurities are dealt with in chapter five. A separate chapter has been compiled to deal with one of the most up-to-date problems in contemporary pharmaceutical analysis, the estimation of enantiomeric purity of chiral drugs. Chapter seven is devoted to various approaches to solve the problem of polymorphic modifications as impurities. Since in the broader sense of the word the microbiological purity of drugs and drug products also belongs to this circle, the most important information from this field is summarised in chapter eight. After the mainly methodology-oriented chapters, the final one concentrates on four groups of drugs (peptides, biotechnological products, antibiotics and steroids) in order to demonstrate the use of the methods described earlier.

CUT & PASTE:

http://rapidshare.de/files/39159476/Vol_4.zip.html Identification and Determination of Impurities in Drugs



Pharmaceutical Stress Testing (Drugs and the Pharmaceutical Sciences)(Excellent Book)

Pharmaceutical Stress Testing (Drugs and the Pharmaceutical Sciences)

Author: Steven W. Baertschi (Editor)
Publisher: Informa Healthcare
PDF | 504 pages | 7,7mb | English language | ISBN 0824740211


The first book devoted to the topic, this reference discusses the predictive power and limitations of current stress testing strategies and emphasizes the critical role of stress testing in the determination of the stability characteristics of pharmaceuticals-offering an extensive compilation of drug degradation studies from real-world examples in the literature.

http://rapidshare.com/files/5013454/pharmastress.rar

password = www.AvaxHome.ru



Monday, July 28, 2008

Know Your Pharma Industry(Part-II)

II Patent:
a. Definition :- An exclusive right given to the innovator by the government for certain period to protect his innovation from others.
[or]
It is defined as a monopoly right given for an invention by the government to the inventor for certain period.
Under united states law, four types of patents issued.
1. Utility patents 2. Design patents 3. Plant patents 4. Provisional Patents:
1. Utility patents:- These patents covers processes, machines, manufacture or composition of matter and new and useful improvements.
Process: Method of treating cancer, use of a known chemical agent which was not known to have herbicidal properties. Method of nondestructive testing of composite materials .
Machines: A device to detect estrus in cow, A particle board blender, An electronic animal hoof force detection system.
Manufacture: Mutated proteins & Monoclonal Anybodies
Composition of matter: A physical utility where the substance itself is the important element , a new chemical compound, veterinary antibodies pure form of naturally occurring substance .
Improvements:- Improvement of above paten table matter if it is distinct.
2. Design patents :- US law provides for design patent protection for the appearance or ornamental design of a article. The form of a design patent is 14 years.
3. Plant patents;- Plant utility patent protection & available for biotechnology, processes, genes, seeds, plant parts, cultivates and hybrids. Plant protection is available under the plant patent act for a sexually reproduced plants only Ex: Apricot trees, cheery trees bent grass seed.
4. Provisional patents:- Provisional, can provide up to twelve months to further develop the invention, determine marketability acquire funding or capital, seek licensing or manufacturing. There are four 4 types of paragraphs in ANDA submission:1.Paragraph I: This is for applying fresh patent, there shouldn’t be any same patent.2. Paragraph II: This is to do and follow the existing patent up to its expiring.3. Paragraph III : This is the procedure to enter into the market” after expiring of patent
4. Paragraph IV: This is the procedure of challenging and showing that ‘The existing patent is non-infringing and invalidated.’
Intellectual property rights:- (IPR):- Responsibilities:-
Preparation of Dossier:-
Introduction, molecular formula, molecular structure, CAS number and chemical name.
Patent status, patent details & patent expiry.
Synthetic pathway:
Patent evaluation, literature collection.
Patent challenging paragraph IV
Infringing: - If the process is said to be infringing then it matching with that of prior act.
Non infringing: - If the process is said to be non infringing if it does not matching with prior act.
Prior act:- The information which is already disclosed or available.
Bio equivalence:- In all aspects strength and stability to be equivalent to that of innovator product. IPA: Indian patent act.
Patent: “A patent is a set of legal rights, that allows the inventor of a novel new or other wise useful invention to prevent others from making selling or even using the invention”
Intellectual properties :- Patents, Trademarks, copyrights, trade secrets, designs are forms of intellectual properties.
You have right to other intellectual prosperities without getting it registered with office or authority of government.
Patent has to be registered with patent office in order to on title you for protection. Importance of generics market.
Objective :
· Drug approval process for generics in us
· Role of us FDA in approving generics products
Hatch- waxman Act :
· Enacted by US Government in 1984.
· Legislated in response to growing concern over price of Drug spiraling out of control
· Gives rewards / incentives to generics companies who successfully challenge innovator patents
Introduction of TRIPS Agreement :
Trips : Trade related aspects of intellectual property rights
SALIENT FEATURES :
· First pronounced in year 1995
· Most of the countries are rignatovies to TRIPS
· Main objective is to bring in the system of uniform patent protection throughout the world.
· Sets certain minimum standards of patens legislation to be followed by all members countries.
· Most important condition required by TRIPS is “introduction product patent “
Patent law in India :
· Product patents
· Exclusive marketing Rights product patents
· Whether TRIPS regime will lead to increase in prices Drugs
· Patenting of traditional knowledge bases of indigenous need.
Aspects of FDA process:

In case of generic approval for new chemical entities innovator gets a minimum period of 5 years of exclusivity.
Term of protection given to inventor is 20 years standard from date of filing.
Minimum requirements for patent ability:- In order to grant a patent, paten office requires your application to fulfill 2 criteria’s, namely :
1. Novelty 2. Utility 3. Obviousness.
1. Novelty: Invention claiming must be new should not described by any publication before date of filling of application in patent office.
2. Utility: Composition /compound/formulation is applied for, & must have been shown to animal test.
Obviousness:
3. Efficacy in human being does not need to prove.
Patents listed in orange book can not be challenged by generic company up to 5 to 6 years of market exclusivity. If innovator files an NDA for a different chemical entity which is related to originally approve Drug, then the innovator will be awarded 3 years of marketing exclusivity.
II b
1.) Abbreviated New Drug Application: It is a formal application to market a new generic drug in USA.
ANDA: one the patent life of a successful drug inventor has expired, other companies are allowed to manufacture and cell generic versions of they till need FDA’s specific approval for these generic products, for which they submit on ANDA.
Abbreviated in the sense that there is no requirement to include clinical data to support safety or efficacy that has already demonstrated by drug inventor.
However the ANDA must demonstrate the bio equivalence of the proposed generic product to the innovator drug.
2. NDA: New Drug Application: - Formal application to market a new drug in USA.
INDA: - Investigational new drug application: Document submitted to FDA prior to commence clinical trials.
ANDA can only be filed by generic company in the last year of market inclusively, of the innovator.
II C
Definitions:
Process suitability:- The established capacity of the manufacturing process to produce effective and reproducibility of results consistently.
Accelerated testing: Studies designated to increase the rate of chemical degradation or physical change of an active drug substance or drug product by using storage conditions as a part of the formal definitive storage programme
Rejected material: Any material of item that has been determined to be unacceptable for the specified use.
Theoretical yield: The quantity that would be produced at any appropriate phase of manufacture processing or packing of a drug product based upon the quantity of components to be used, in the absence of any loss or error in actual production.
Actual yield: The quantity that is actually proceed at any appropriate phase of manufacture processing or packing of a drug product .
Percentage of theoretical yield: The ratio of actual yield to the theoretical yield .
Cross contamination:- An undesired introduction of one or more materials .
Shelf life or expiration dating period:- The time interval that a drug product is expected to remain within the approved shelf life specification provided that is stored under the conditions defined on the label.
In process testing: Testing performed during production to monitor & to adjust the process to ensure that the drug substance or intermediate conforms to its specifications.
Recovery:- The appropriate processing of materials to make them for further use.
Impurity: - Any component of a drug substance which is not the chemical entity defined as a new drug substance. OR Impurity is a foreign particle (material) which is present along with desired product.
Impurity profile:- A description o identified & unidentified impurities present in a new drug substance.
Potential impurity:- An impurity that theoretically can arise during manufacture or storage.
Extraneous impurities:- An impurity arising from any source extraneous in the manufacturing process, due to conformation.
Active pharmaceutical ingredients:- (API) : A substance produced by chemical synthesis, formation recovery from natural materials that is used as drug component labeled.
Pharmaceutical:- It is defined as a mixture of binding agents preservatives, micro cellulose coatings, execipients, packing material & other ingredients which cures side effects.
Starting material:- USFDA has defined as it is incorporated into the new drug substance as an important structure element, as it is commercially available.
Intermediate:- A material produced during the step of the synthesis of a new drug substance that undergoes further chemical transformation before it becomes a new drug substance.
Reagents:- A substance other than starting material, intermediate or solvent that is used in the manufacture of new drug substance.
Solvent: An in organic liquid used as a vehicle for the preparation solutions & suspensions in the synthesis of a new drug substance.
Pharmacopoeia:- It is the book containing a list of medicinal drugs and directions for the use.
Ligand:- An agent with a strong affinity to a metal ion.
Protocol:- It is the clear procedure & clear picture of experimental observations.
COD: Chemical oxygen demand:- The amount of oxygen needed to decompose a chemical in air.
Known impurity:_ structural conformation has been achieved.
Unknown impurity:- Structural conformation has not been achieved.
Infringing: - It the process is said to be infringing, than it is matching with prior art’s (prior art: Information which is already available/.disclosed
Non infringing:- If the process is said to be non-infringing if it doesn’t matches with that of the information which is already disclosed/ Available (prir art).
IIC
Abbreviations:
1. GATT : General Agreement an Trade & Tariff.
2. SBOA : Summary Based on Approval
3. EMR : Exclusive market vights.
4. IPA : Indian patent act.
5. ETP : Effluent treatment plant.
6. BOD : Biological oxygen demand.
7. COD : Chemical oxygen demand
8. TDS : Total dissolved salts/solids.
9. COC : Certificate of compliance.
10. USFDA: United states food and drug administration.
11. ISO : International organization for standardization.
12. LOD : Limit of detection.
13. LOQ : Limit of Quantification.
14. MSDS : Material safety data sheets
15. PDE : Permitted daily exposure.
16. TDI : Tolerable daily intake
17. ADI : Acceptable daily intake
18. TOC : Total organic carbon analysis
19. USP : United states pharmacopoeia
20. ACS : American chemical society.
21. RM : Regulatory market (regulations are stringent)
22. LRM : Less Regulatory market.

II C
Definition:
Reference standard:- It is a substance prepared to use as the standard in assay, identification purity.
LOD: Limit of detection: The lowest concentration of a analyte in a sample that can be detected, but not necessarily quantiated under the stated experimental conditions.
LOD: Signal to noise ration 2 & 3 is acceptable, 2 to 3 times of LOD=LOQ.
LOQ: Limit of quantification:- The lowest concentration of analyte in a sample , that can be determined with acceptable precision accuracy under the stated experimental conditions. Signal to noise ration 10.1 is acceptable.
Bulk density: The amount of drug substance present in unit volume.
Total dissolved solids: (TDS) : The determination of total amount of organic / in organic solids dissolved in a solution of unit volume.
Hazard: Defined as the potential for harmful effects.
Reactivity: It is the tendency of a substance to undergo chemical reaction.
In compatibles:- These are the substances which are reactive with each other.
Flash point: It is the lowest temperature of a substance at and above, which it can produce a fire or explosion, if 1. Vapor concentration of the substance is with in flammability range 2. If an ignition source is available.
Threshold limit value (TLV):- It is the maximum concentration of a chemical in air to which a person can be exposed for a certain period.
Flammability range:- Range between lower exposure limit where it can produce fir or explosion .
Fire Extinguishers types:
Fire A solids -------------------------- Water, sand & CO2
Fire B liquids ------------------------- Foam & CO2
Fire C gas ------------------------- Dry chemical powder (DCP)
Fire D&E Electrical ----------------- DCP & CO2
ISO : International Organization for Standardization.
ISO : 9000 - Certification.
ISO : 9001 - Quality, design, & manufacturing\
ISO : 9002 - Manufacturing & Quality
ISO : 14001 - Environmental safety
IID
Medical terms related to symptoms:
1. Analgesia: Loss of sensitivity to pain
2. Anesthesia: Loss of feeling
3. Ashyxia: Suffocation
4. Bronchitis Coughing, difficult in breathing
5. Bruise: Discolored spot
6. Cancer Abnormal tissue growth.
7. Conjunctivitis: Inflamed and reddened eyes
8. Convulsions Violent body spasms
9. Depression Decrease in activity
10. Dermatitis Reddened skin.
11. Dizziness Feeling faint
12. Drocusiness Falling asleep
13. Edema Swelling
14. Fatigue Tiredness
15. Gastroenteritis Inflammation of the stomach & intestine.
16. Hallucination: Strongly experienced false perception which has compulsive sense of realty object of current.
17. Hematuvia Blood in the urine
18. Hemorrhage Bleeding
19. Inflammation Swelling, redness, warmth
20. Insomnia Inability to obtain normal sleep.
21. Jaundice Yellow discolovation of skin or eyes
22. Lacrimaiton Excessive eye tearing
23. Malnutrition Inadequate diet
24. Nausea Feeling of need to vomit.
25. Palpitations Forceful heart beat.
26. Paralysis loss of ability to move limbs
27. Seizure: Convulsion
28. Spasm Convulsive muscular contraction
29. Swelling Enlargement
30. Tremors Shaking, trembling
31. Vertigo Feeling of whirling motion